• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, August 22, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

New drug combination shows promise for resistant leukaemia

Bioengineer by Bioengineer
May 19, 2016
in Cancer
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE
Credit: The Walter and Eliza Hall Institute of Medical Research

Patients with acute myeloid leukaemia (AML) can look forward to the development of new therapies following the discovery by Walter and Eliza Hall Institute researchers of a new way to kill cells that are dangerously multiplying.

A process known as apoptosis (programmed cell death) — which is a natural and necessary response to keep the proliferation of human cells in check — is interrupted in cancers, including AML, leading to unchecked cell growth.

Institute researcher Dr Gabriela Brumatti and her PhD student Chunyan Ma are part of a team, led by Professor John Silke from the Institute and Professor Paul Ekert from the Murdoch Childrens Research Institute in Melbourne, investigating ways to target particular types of AML, hoping to increase the chance of a cure for the patient while limiting damage to healthy cells.

Dr Brumatti said traditional chemotherapies, which induce apoptosis, had a high relapse rate. For example, within five years of completing treatment 50 per cent of AML patients suffer a relapse of their cancer. Of those who relapse, only 50 per cent survive.

Her team tried a ‘blue sky’ approach to their research and inhibited apoptosis of AML cells in order to unleash an alternative form of cell death called necroptosis. They found this necroptosis cell death pathway was more effective at killing AML than apoptosis. These findings have just been published in the research journal, Science Translational Medicine.

In preclinical trials they used a combination of drugs — birinapant, a new anti-cancer drug, and emricasan, a US Food and Drug Administration (FDA) approved inhibitor of apoptosis — to kill AML.

“It has been speculated that inducing necroptosis might be an effective way to kill cancer cells”, said Professor Silke. “Our work now demonstrates clearly it is a clinically feasible and safe approach.”

Dr Brumatti said since cancer cells often acquire resistance to traditional chemotherapy-induced apoptosis, this novel type of chemotherapy had the potential to be used to treat otherwise impossible to treat leukaemias.

###

This work was supported by a grant from the Leukemia & Lymphoma Society, the National Health and Medical Research Council (NHMRC), and an Association pour le Recherche contre le Cancer (ARC) fellowship with additional support from the Australian Cancer Research Foundation, the Victorian State Government Operational Infrastructure Support, and the NHMRC Independent Research Institutes Infrastructure Support Scheme.

Media Contact

Ebru Yaman
[email protected]
042-803-4089
@WEHI_research

Home

The post New drug combination shows promise for resistant leukaemia appeared first on Scienmag.

Share12Tweet7Share2ShareShareShare1

Related Posts

β-Elemene’s Therapeutic Promise for Glioma, CNS Diseases

β-Elemene’s Therapeutic Promise for Glioma, CNS Diseases

August 22, 2025
AI Detects Cancer Cases Overlooked by Pathologists

AI Detects Cancer Cases Overlooked by Pathologists

August 22, 2025

Colibactin-Producing E. coli Associated with Elevated Colorectal Cancer Risk in FAP Patients

August 22, 2025

Osimertinib Myotoxicity: FDA Data Reveals Risks

August 22, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Molecules in Focus: Capturing the Timeless Dance of Particles

    141 shares
    Share 56 Tweet 35
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    114 shares
    Share 46 Tweet 29
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    81 shares
    Share 32 Tweet 20
  • Modified DASH Diet Reduces Blood Sugar Levels in Adults with Type 2 Diabetes, Clinical Trial Finds

    60 shares
    Share 24 Tweet 15

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

APS PRESS Unveils Third Edition of Cotton Industry’s Premier Diagnostic Reference

Birth Weight Linked to Maternal, Neonatal PFOS Levels

β-Elemene’s Therapeutic Promise for Glioma, CNS Diseases

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.